Back to Search

A Phase 2 Trial of Ixazomib for Kaposi Sarcoma

  • Protocol Number: 202307164
  • Principal Investigator: Ratner, Lee
  • Cancer Types: Sarcoma

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

This phase II trial studies how well ixazomib works in treating patients with Kaposi sarcoma. Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Protocol Interventions

Ixazomib Citrate, Quality-of-Life Assessment, Questionnaire Administration